Merck KGaA (FRA:MRK) has been assigned a €105.00 ($125.00) price objective by analysts at Independent Research GmbH in a report released on Monday, August 28th. The firm currently has a “neutral” rating on the healthcare company’s stock.
A number of other research analysts have also recently commented on the company. BNP Paribas set a €114.00 ($135.71) target price on Merck KGaA and gave the company a “buy” rating in a research note on Wednesday, May 10th. DZ Bank AG reissued a “neutral” rating on shares of Merck KGaA in a research note on Saturday, May 20th. equinet AG set a €91.00 ($108.33) price target on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Saturday, May 20th. Warburg Research set a €116.00 ($138.10) price target on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Tuesday, June 20th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of Merck KGaA in a research report on Friday, August 4th. Thirteen equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of €108.38 ($129.02).
Shares of Merck KGaA (FRA:MRK) traded up 2.030% on Monday, reaching €98.204. The company’s stock had a trading volume of 1,561 shares. The company’s 50 day moving average is €93.27 and its 200-day moving average is €102.52. The firm has a market cap of €42.70 billion and a price-to-earnings ratio of 25.601. Merck KGaA has a 1-year low of €89.00 and a 1-year high of €115.00.
WARNING: This story was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://ledgergazette.com/2017/09/13/merck-kgaa-mrk-pt-set-at-105-00-by-independent-research-gmbh.html.
Merck KGaA Company Profile
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.